Cell Therapeutics, Inc. to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data

SEATTLE, June 18 /PRNewswire-FirstCall/ -- On Wednesday, June 18, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss agreement with Bayer Schering Pharma for access to Phase III Zevalin(R) FIT Trial data.

Live audio webcast at http://www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, or
Lindsey Jesch, +1-206-272-4347, fax, +1-206-272-4434, media@ctiseattle.com,
or investors, Ed Bell, +1-206-272-4345, fax, +1-206-272-4434,
invest@ctiseattle.com, all of Cell Therapeutics, Inc.

Web site: http://www.celltherapeutics.com/